A Phase 1 interventional study of Nintedanib high dose and Nintedanib low dose in Carcinoma, Hepatocellular, sponsored by Boehringer Ingelheim. Completed at 5 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-02-12.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Carcinoma, Hepatocellular with a site in Japan — 17 open to participants now, 32 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Japan.
Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, this one is the 86th largest by enrollment of the 103 interventional ones that give a count, is one of 5 that started in 2012, is one of 29 in phase 1, and was the 33rd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →17 of the 115 studies in Carcinoma, Hepatocellular with a site in Japan are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan, United States, Australia and 11 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Boston Scientific Corporation · Sites in Japan
Ages 18+
Pfizer · Sites in Japan, United States, China and 2 more countries
Ages 18+
Zymeworks BC Inc. · Sites in Japan, United States, Ireland and 3 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 37 · Phase 3 34 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 182 across the 103 interventional studies, 563 across the 12 observational. Of the 76 that completed or were terminated, 43 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 115 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
12 of the studies in Carcinoma, Hepatocellular with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT03833700Eisai Co., Ltd.A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | 2027-03-31 |
| NCT06427941BeOne MedicinesA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
Drug: Nintedanib high dose · Drug: Nintedanib medium dose
patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
Drug: Nintedanib low dose · Drug: Nintedanib medium dose · Drug: Nintedanib high dose
twice daily oral dosing
twice daily oral dosing
twice daily oral dosing
twice daily oral dosing
twice daily oral dosing
Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib
The MTD is based on the incidence of Dose Limiting Toxicities (DLTs). A drug-related AE was considered as a DLT if one of the following met: CTCAE grade 4 thrombocytopenia of any duration, CTCAE grade 4 neutropenia lasting for ≥8 days, CTCAE grade 4 febrile neutropenia of any duration, CTCAE grade 3 or 4 non-haematologic toxicity (with the following exception: Alopecia, Vomiting, nausea, or diarrhoea with no adequate supportive care, Transient electrolyte abnormality, which resolves spontaneously or can be corrected with appropriate treatment within 3 days, Liver toxicity), Liver enzyme toxicity of AST, ALT, alkaline phosphatase \[ALP\] elevation \>5x ULN, or total bilirubin \>3x ULN if baseline liver enzymes are within the normal range, or AST, ALT or ALP \> baseline value + 4x ULN if the baseline value is elevated. The MTD was determined to be 200mg bid.
Time frame: up to 28 days
Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0
Objective response (Complete response (CR) + Partial response (PR), regardless of confirmation) is derived from a patient's best objective response by RECIST. Best objective response is calculated based on the "overall" visit response from each assessment. Best objective response represents the best response a patient has had during their time in the study up until progression, last evaluable assessment in the absence of progression or the start of subsequent anti-cancer therapy. For patients whose progression event is death, best objective response will be calculated based on data up until the last evaluable RECIST assessment prior to death.
Time frame: up to 28 months
Progression Free Survival (PFS)
PFS is defined as the duration from start date of the study treatment to PD according to RECIST 1.0, or any death whichever occurs earlier.
Time frame: up to 28 months
Time to Progression (TTP)
TTP is defined as the duration from the start date of the study treatment to PD according to RECIST 1.0.
Time frame: up to 28 months
Number of Participants With Response by Alpha Fetoprotein (AFP)
Response by AFP is defined as 20% or more decline in AFP between the baseline value and the AFP value after three courses (12 weeks) of therapy. If patients only receive two courses of therapy the AFP value after two courses (8 weeks) will be used for the analysis.
Time frame: up to 28 months
| Milestone | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Started | 4 | 12 | 3 | 4 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 12 | 3 | 4 | 7 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 3 | 12 | 3 | 3 | 7 |
The MTD is based on the incidence of Dose Limiting Toxicities (DLTs). A drug-related AE was considered as a DLT if one of the following met: CTCAE grade 4 thrombocytopenia of any duration, CTCAE grade 4 neutropenia lasting for ≥8 days, CTCAE grade 4 febrile neutropenia of any duration, CTCAE grade 3 or 4 non-haematologic toxicity (with the following exception: Alopecia, Vomiting, nausea, or diarrhoea with no adequate supportive care, Transient electrolyte abnormality, which resolves spontaneously or can be corrected with appropriate treatment within 3 days, Liver toxicity), Liver enzyme toxicity of AST, ALT, alkaline phosphatase \[ALP\] elevation \>5x ULN, or total bilirubin \>3x ULN if baseline liver enzymes are within the normal range, or AST, ALT or ALP \> baseline value + 4x ULN if the baseline value is elevated. The MTD was determined to be 200mg bid.
| participants | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib | 0 | 0 | 0 | 0 | 0 |
Objective response (Complete response (CR) + Partial response (PR), regardless of confirmation) is derived from a patient's best objective response by RECIST. Best objective response is calculated based on the "overall" visit response from each assessment. Best objective response represents the best response a patient has had during their time in the study up until progression, last evaluable assessment in the absence of progression or the start of subsequent anti-cancer therapy. For patients whose progression event is death, best objective response will be calculated based on data up until the last evaluable RECIST assessment prior to death.
| participants | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 | 0 | 0 | 0 | 0 | 0 |
PFS is defined as the duration from start date of the study treatment to PD according to RECIST 1.0, or any death whichever occurs earlier.
| months | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 6.05 (0.95 to 8.25) | 2.76 (1.74 to 5.42) | 7.26 (3.68 to 7.39) | 2.40 (1.48 to 6.88) | 2.76 (0.95 to 5.62) |
TTP is defined as the duration from the start date of the study treatment to PD according to RECIST 1.0.
| months | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Time to Progression (TTP) | 6.05 (0.95 to 8.25) | 2.76 (1.74 to 5.42) | 7.26 (3.68 to 7.39) | 2.40 (1.48 to 6.88) | 2.76 (0.95 to 5.62) |
Response by AFP is defined as 20% or more decline in AFP between the baseline value and the AFP value after three courses (12 weeks) of therapy. If patients only receive two courses of therapy the AFP value after two courses (8 weeks) will be used for the analysis.
| participants | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Number of Participants With Response by Alpha Fetoprotein (AFP) | 2 | 1 | 1 | 1 | 1 |
Collected over up to 67 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group I: Nintedanib 150mg Bid | — | 0/4 (0%) | 4/4 (100%) |
| Group I: Nintedanib 200mg Bid | — | 4/12 (33.3%) | 12/12 (100%) |
| Group II: Nintedanib 100mg Bid | — | 1/3 (33.3%) | 3/3 (100%) |
| Group II: Nintedanib 150mg Bid | — | 2/4 (50%) | 4/4 (100%) |
| Group II: Nintedanib 200mg Bid | — | 3/7 (42.9%) | 7/7 (100%) |
| Event | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 1/12 | 1/3 | 2/4 | 1/7 |
| GastroenteritisInfections and infestations | 0/4 | 0/12 | 1/3 | 0/4 | 0/7 |
| AscitesGastrointestinal disorders | 0/4 | 0/12 | 0/3 | 1/4 | 0/7 |
| PyrexiaGeneral disorders | 0/4 | 0/12 | 0/3 | 0/4 | 1/7 |
| Drug-induced liver injuryHepatobiliary disorders | 0/4 | 0/12 | 0/3 | 0/4 | 1/7 |
| Tumour embolismNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/12 | 0/3 | 0/4 | 1/7 |
| Immune thrombocytopenic purpuraBlood and lymphatic system disorders | 0/4 | 1/12 | 0/3 | 0/4 | 0/7 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/12 | 0/3 | 0/4 | 0/7 |
| HyponatraemiaMetabolism and nutrition disorders | 0/4 | 1/12 | 0/3 | 0/4 | 0/7 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 1/12 | 0/3 | 0/4 | 0/7 |
| Event | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/4 | 7/12 | 0/3 | 4/4 | 1/7 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 | 4/12 | 1/3 | 4/4 | 2/7 |
| VomitingGastrointestinal disorders | 0/4 | 6/12 | 0/3 | 3/4 | 0/7 |
| FatigueGeneral disorders | 2/4 | 1/12 | 2/3 | 3/4 | 0/7 |
| Blood bilirubin increasedInvestigations | 0/4 | 1/12 | 1/3 | 3/4 | 0/7 |
| LeukopeniaBlood and lymphatic system disorders | 0/4 | 0/12 | 2/3 | 0/4 | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 2/4 | 0/12 | 2/3 | 1/4 | 0/7 |
| Alanine aminotransferase increasedInvestigations | 1/4 | 0/12 | 2/3 | 1/4 | 1/7 |
| Aspartate aminotransferase increasedInvestigations | 1/4 | 3/12 | 2/3 | 2/4 | 1/7 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/4 | 2/12 | 2/3 | 2/4 | 2/7 |
| Age, Continuous(years) | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid | Total |
|---|---|---|---|---|---|---|
| Mean | 67.0 ± 14.72 | 63.1 ± 9.84 | 73.3 ± 2.31 | 66.5 ± 6.56 | 67.4 ± 4.35 | 66.1 ± 8.81 |
| Sex: Female, Male(Participants) | Group I: Nintedanib 150mg Bid | Group I: Nintedanib 200mg Bid | Group II: Nintedanib 100mg Bid | Group II: Nintedanib 150mg Bid | Group II: Nintedanib 200mg Bid | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 3 | 2 | 1 | 9 |
| Male | 2 | 11 | 0 | 2 | 6 | 21 |
The record gives a start of May 2012, a primary completion of Nov 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.